Cite
Reinhardt B, Habib O, Shaw KL, et al. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. Blood. 2021;138(15):1304-1316doi: 10.1182/blood.2020010260.
Reinhardt, B., Habib, O., Shaw, K. L., Garabedian, E., Carbonaro-Sarracino, D. A., Terrazas, D., Fernandez, B. C., De Oliveira, S., Moore, T. B., Ikeda, A. K., Engel, B. C., Podsakoff, G. M., Hollis, R. P., Fernandes, A., Jackson, C., Shupien, S., Mishra, S., Davila, A., Mottahedeh, J., Vitomirov, A., Meng, W., Rosenfeld, A. M., Roche, A. M., Hokama, P., Reddy, S., Everett, J., Wang, X., Luning Prak, E. T., Cornetta, K., Hershfield, M. S., Sokolic, R., De Ravin, S. S., Malech, H. L., Bushman, F. D., Candotti, F., & Kohn, D. B. (2021). Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. Blood, 138(15), 1304-1316. https://doi.org/10.1182/blood.2020010260
Reinhardt, Bryanna, et al. "Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency." Blood vol. 138,15 (2021): 1304-1316. doi: https://doi.org/10.1182/blood.2020010260
Reinhardt B, Habib O, Shaw KL, Garabedian E, Carbonaro-Sarracino DA, Terrazas D, Fernandez BC, De Oliveira S, Moore TB, Ikeda AK, Engel BC, Podsakoff GM, Hollis RP, Fernandes A, Jackson C, Shupien S, Mishra S, Davila A, Mottahedeh J, Vitomirov A, Meng W, Rosenfeld AM, Roche AM, Hokama P, Reddy S, Everett J, Wang X, Luning Prak ET, Cornetta K, Hershfield MS, Sokolic R, De Ravin SS, Malech HL, Bushman FD, Candotti F, Kohn DB. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. Blood. 2021 Oct 14;138(15):1304-1316. doi: 10.1182/blood.2020010260. PMID: 33974038; PMCID: PMC8525336.
Copy
Download .nbib